Monoclonal Antibody Therapy and Docetaxel in Treating Women With Metastatic or Recurrent Breast Cancer

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically confirmed metastatic or recurrent breast carcinoma
• •* Unresectable disease
• •* Previously treated with no more than 2 chemotherapy regimens for metastatic disease OR
• •* Recurrent within 6 months of adjuvant chemotherapy
• •Must have one of the following:
• •* Measurable disease
• •* Positive bone scan and elevation of serum tumor marker for adenocarcinoma
• •* Serum levels must have increased over 2 consecutive measurements and exceed at least 2 times upper limit of normal
• •Lewis-y antigen expression documented by immunohistochemistry
• •No brain metastases that are uncontrolled or require active treatment (including steroids)
• •Hormone receptor status:
• •* Not specified
• •PATIENT CHARACTERISTICS:
• •Age:
• •18 and over
• •Sex:
• •Female
• •Menopausal status:
• •Not specified
• •Performance status:
• •ECOG 0-2
• •Life expectancy:
• •At least 3 months
• •Hematopoietic:
• •Hemoglobin at least 10 g/dL
• •Absolute neutrophil count at least 1,500/mm\^3
• •Platelet count at least 100,000/mm\^3
• •No bleeding diathesis
• •Hepatic:
• •Bilirubin no greater than 1.5 mg/dL
• •SGOT no greater than 2.5 times normal
• •Alkaline phosphatase no greater than 2.5 times normal (unless documented bony metastasis present)
• •Amylase/lipase less than 1.5 times normal
• •Hepatitis B and C negative
• •No hepatic failure
• •Renal:
• •Creatinine no greater than 1.5 times upper limit of normal
• •No renal failure
• •Cardiovascular:
• •LVEF greater than 50% by echocardiogram or MUGA scan
• •No congestive heart failure
• •Other:
• •HIV negative
• •No antibody present that detects monoclonal antibody BR96 in serum
• •No peripheral neuropathy grade 2 or greater
• •No dementia or altered mental status
• •No other serious underlying medical condition that would preclude study participation
• •No prior allergic reactions to recombinant human or murine proteins
• •No uncontrolled peptic ulcer disease
• •No active viral, bacterial, or systemic fungal infections
• •No other primary malignancy except nonmelanoma skin cancer or carcinoma in situ of the cervix
• •No serious nonmalignant disease
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy:
• •At least 8 weeks since prior therapeutic or diagnostic murine/humanized/human chimeric antibodies
• •Chemotherapy:
• •See Disease Characteristics
• •At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas, carboplatin, mitomycin, or anthracyclines)
• •No prior cumulative anthracycline of 300 mg/m2 or more
• •No concurrent antineoplastic agents
• •Endocrine therapy:
• •See Disease Characteristics
• •At least 4 weeks since prior hormonal therapy
• •No concurrent hormonal therapy except estrogen replacement
• •Radiotherapy:
• •At least 4 weeks since prior radiotherapy
• •Surgery:
• •See Disease Characteristics
• •Other:
• •No other concurrent experimental agents
• •No concurrent immunosuppressive medications